Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Ibrutinib and TEDDI-R in Primary CNS Lymphoma
NCT02203526Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibrutinib in primary central nervous system lymphoma (PCNSL) (5 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and Feasibility, Maximum Tolerated Dose and 1 more. Started Aug 2014; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT02203526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203526.